依达拉奉注射液联合丁苯酞对急性高原脑梗死患者血清炎症因子、氧自由基及血管内皮功能的影响  

Impact of the combination of edaravone injection and butylphthalide therapy on serum inflammatory markers,oxygen free radicals,and endothelial function in patients with acute high-altitude cerebral infarction

作　　者：杨丽 鲁雪 杜志明 王晓红 Yang Li;Lu Xue;Du Zhiming;Wang Xiaohong(Department of Pharmacy,the Fifth People's Hospital of Qinghai Province,Xining 810007,China;Department of Preparation,Qinghai Provincial Tibetan Hospital,Xining 810007,China)

机构地区：[1]青海省第五人民医院药剂科,青海西宁810007 [2]青海省藏医院制剂科,青海西宁810007

出　　处：《中华脑血管病杂志(电子版)》2024年第6期542-548,共7页Chinese Journal of Cerebrovascular Diseases(Electronic Edition)

摘　　要：目的探究依达拉奉注射液联合丁苯酞对急性高原脑梗死(AHACI)患者血清炎症因子、氧自由基及血管内皮功能的影响。方法选取2021年6月至2022年6月在青海省第五人民医院接受治疗的90例AHACI患者为研究对象。采用随机数字分配法将患者分为丁苯酞组和联合组,每组各45例患者。丁苯酞组给予丁苯酞治疗,联合组在丁苯酞组治疗基础上联合依达拉奉注射液进行治疗。2组均持续治疗2周。应用美国国立卫生研究院卒中量表(NIHSS)评估治疗前后神经功能缺损程度,评价2组治疗疗效并采用χ^(2)检验比较组间疗效差异;检测2组治疗前后血清炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)]、氧自由基[超氧化物歧化酶(SOD)、丙二醛(MDA)、晚期氧化蛋白产物(AOPP)]、血管内皮生长因子(VEGF)及内皮素1(ET-1)水平。采用配对t检验比较组内相关指标治疗前后的差异,采用两独立样本t检验比较组间各指标的差异。结果联合组临床治疗总有效率高于丁苯酞组[80.00%(36/45)vs 95.56%(43/45);χ^(2)=5.075,P=0.024]。治疗后,hs-CRP、IL-6及TNF-α含量明显下降,且联合组低于丁苯酞组[(7.35±2.01)mg/L vs(9.56±2.09)mg/L;(8.03±2.56)μg/L vs(9.68±2.11)μg/L;(46.37±10.23)ng/ml vs(52.83±12.55)ng/ml],差异具有统计学意义(t=5.113、3.336、2.676,P<0.001、=0.003、=0.014);联合组NIHSS评分低于丁苯酞组[(8.56±1.34)分vs(11.32±1.12)分],差异具有统计学意义(t=10.602,P<0.001)。治疗2周后,2组患者血清SOD含量明显提高,且联合组高于丁苯酞组[(324.12±18.65)U/ml vs(246.13±19.35)U/ml];2组患者MDA与AOPP含量均明显降低,且联合组低于丁苯酞组[(5.63±0.73)μg/L vs(7.19±0.95)μg/L;(72.14±6.25)ng/ml vs(98.16±9.26)ng/ml],差异均具有统计学意义(t=19.467、8.735、15.624,P均<0.001)。2组患者治疗后血清VEGF含量升高,且联合组高于丁苯酞组[(502.36±60.13)ng/ml vs(422.34±60.12)ng/ml],ET-Objective To explore the effects of edaravone injection combined with butylphthalide on serum inflammatory factors,oxygen free radicals,and endothelial function in patients with acute highaltitude cerebral infarction(AHACI).Methods A total of 90 AHACI patients treated at Qinghai Provincial Fifth People&apos;s Hospital from June 2021 to June 2022 were included.Patients were randomly assigned to either a butylphthalide group or a combination group,with 45 patients in each.The butylphthalide group received butylphthalide treatment alone,while the combination group received edaravone injection in addition to butylphthalide treatment.Both groups underwent a 2-week treatment regimen.The National Institutes of Health Stroke Scale(NIHSS)was used to evaluate the degree of neurological deficit before and after treatment.The efficacy of the treatment was assessed,and the chi-square test was applied to compare the efficacy between the two groups.Serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],oxygen free radicals[superoxide dismutase(SOD),malondialdehyde(MDA),advanced oxidation protein products(AOPP)],vascular endothelial growth factor(VEGF),and endothelin-1(ET-1)levels were measured before and after treatment.Paired t-tests were used to assess changes within the groups,and independent sample t-tests were used to compare differences between the groups.Results The combination group demonstrated a higher total effective rate of clinical treatment compared to the butylphthalide group(80.00%[36/45]vs 95.56%[43/45];χ^(2)=5.075,P=0.024).After treatment,hs-CRP,IL-6,and TNF-αlevels significantly decreased,with lower levels in the combination group[(7.35±2.01)mg/L vs(9.56±2.09)mg/L;(8.03±2.56)μg/L vs(9.68±2.11)μg/L;(46.37±10.23)ng/ml vs(52.83±12.55)ng/ml],with statistically significant differences(t=5.113,3.336,2.676,P<0.001,=0.003,=0.014).The NIHSS score in the combination group was lower than that in the butylphthalide group[(8.56±1.34)points vs

关 键 词：依达拉奉 丁苯酞 脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]